Neonc Technologies Holdings, Inc. (NTHI)

Neonc Technologies Holdings, Inc. (NTHI) Healthcare & Pipeline Overview

Neonc Technologies Holdings, Inc. is a biotechnology firm specializing in innovative molecular technologies for targeted drug delivery to treat central nervous system (CNS) diseases. Their pipeline features NEO100, currently in Phase 2a clinical trials for glioblastoma, and NEO212, which has completed preclinical testing, positioning them in the competitive biotechnology landscape.

What Is the Investment Thesis for NTHI?

Neonc Technologies Holdings, Inc. presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on targeted drug delivery for CNS diseases addresses a significant unmet medical need. The primary value driver is the successful clinical development and eventual commercialization of NEO100 and NEO212. NEO100, currently in Phase 2a trials for glioblastoma, represents a near-term catalyst. Positive clinical data could significantly increase the company's valuation. NEO212, having completed preclinical testing, offers a mid-term growth opportunity. However, the company's negative profit margin of -169597.9% highlights its reliance on external funding and the inherent risks associated with drug development. The company's high beta of 3.60 indicates significant volatility. Investment is contingent on the successful navigation of clinical trials and regulatory approvals.

Based on FMP financials and quantitative analysis

NTHI Key Highlights

• Market capitalization of $87.78M reflects the company's early stage and potential for growth in the biotechnology sector.
• Gross margin of 100.0% indicates efficient production, although this may not be sustainable as the company scales up and incurs higher operating expenses.
• Profit margin of -169597.9% highlights the company's significant investment in research and development and its lack of revenue-generating products currently.
• Beta of 3.60 suggests the stock is highly volatile compared to the market, reflecting the speculative nature of biotechnology investments.
• Lead product NEO100 is in Phase 2a clinical trials for glioblastoma, representing a key milestone in the company's development.

Who Are NTHI's Competitors?

NTHI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NTHI's Key Strengths?

• Proprietary molecular technology for targeted drug delivery.
• Lead product NEO100 in Phase 2a clinical trials for glioblastoma.
• Experienced management team with expertise in biotechnology and drug development.
• Focus on a specific therapeutic area (CNS diseases).

What Are NTHI's Weaknesses?

• Early-stage company with limited revenue and significant operating losses.
• Reliance on external funding to support research and development activities.
• High risk of clinical trial failure and regulatory setbacks.
• Small team size (8 employees) limits operational capacity.

What Could Drive NTHI Stock Higher?

• Data readout from Phase 2a clinical trials for NEO100 in glioblastoma (expected in late 2026).
• Initiation of clinical trials for NEO212 following completion of preclinical testing (expected in early 2027).
• Potential for strategic partnerships with larger pharmaceutical companies to co-develop and commercialize NEO100 and NEO212.
• Securing additional funding through grants, venture capital, or public offerings.

What Are the Key Risks for NTHI?

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure of NEO100 or NEO212 to demonstrate efficacy or safety in clinical trials.
• Delays in clinical trial timelines or regulatory approvals.
• Competition from larger pharmaceutical companies with greater resources.
• Dependence on external funding to support research and development activities.
• Patent expiration and generic competition.

What Are the Growth Opportunities for NTHI?

• Successful completion of Phase 2a clinical trials for NEO100 in glioblastoma represents a significant near-term growth opportunity. Positive data could lead to increased investor interest, partnerships with larger pharmaceutical companies, and accelerated development towards Phase 3 trials. The global market for glioblastoma treatment is projected to reach billions of dollars, offering substantial revenue potential for Neonc Technologies Holdings, Inc. if NEO100 proves to be an effective therapy. Timeline: 1-2 years.
• Advancement of NEO212 into clinical trials following successful preclinical testing offers a mid-term growth opportunity. NEO212's unique combination of temozolomide and perillyl alcohol could provide improved efficacy and reduced toxicity compared to standard chemotherapy. The market for temozolomide-based therapies is well-established, providing a clear path for commercialization if clinical trials are successful. Timeline: 2-3 years.
• Expansion of the pipeline through the development of additional targeted drug delivery technologies for other CNS diseases represents a long-term growth opportunity. Neonc Technologies Holdings, Inc.'s expertise in molecular technology could be applied to a range of neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The market for CNS therapeutics is vast and growing, offering significant potential for future product development. Timeline: 3-5 years.
• Strategic partnerships with larger pharmaceutical companies to co-develop and commercialize NEO100 and NEO212 could accelerate growth and reduce financial risk. Collaboration with established players in the pharmaceutical industry would provide access to resources, expertise, and distribution networks. Such partnerships could also validate the company's technology and increase its credibility with investors and regulators. Timeline: Ongoing.
• Securing additional funding through grants, venture capital, or public offerings is essential to support the company's ongoing research and development activities. Access to capital will enable Neonc Technologies Holdings, Inc. to advance its pipeline, conduct clinical trials, and build its infrastructure. The ability to attract and retain investors will be critical to the company's long-term success. Timeline: Ongoing.

What Opportunities Does NTHI Have?

• Successful completion of clinical trials and regulatory approval of NEO100 and NEO212.
• Expansion of the pipeline through the development of additional targeted therapies.
• Strategic partnerships with larger pharmaceutical companies.
• Growing market for CNS therapeutics driven by an aging population.

What Threats Does NTHI Face?

• Competition from larger pharmaceutical companies with greater resources.
• Patent expiration and generic competition.
• Changes in regulatory requirements and healthcare policies.
• Economic downturn and reduced investment in biotechnology.

What Are NTHI's Competitive Advantages?

• Proprietary molecular technology for targeted drug delivery provides a competitive advantage.
• Patent protection for NEO100 and NEO212 creates barriers to entry.
• Focus on CNS diseases allows for specialization and expertise in a specific therapeutic area.
• First-mover advantage in developing targeted therapies for glioblastoma.

What Does NTHI Do?

Neonc Technologies Holdings, Inc., incorporated in 2023 and based in Los Angeles, California, is a biotechnology company focused on developing novel molecular technologies for enhanced targeted delivery of therapeutics, particularly for central nervous system (CNS) diseases. The company's mission is to improve treatment outcomes for patients suffering from debilitating CNS disorders by creating more effective and targeted drug delivery systems. Their lead product, NEO100, is currently in Phase 2a clinical trials for the treatment of glioblastoma, an aggressive form of brain cancer. NEO100 leverages the company's proprietary technology to enhance drug delivery directly to the tumor site, potentially improving efficacy and reducing systemic toxicity. Another key asset in their pipeline is NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 has completed preclinical testing and is being prepared for clinical trials. This innovative approach aims to enhance the therapeutic effect of temozolomide, a commonly used chemotherapy drug, while also improving its delivery and reducing side effects. Neonc Technologies Holdings, Inc. is committed to advancing its pipeline of targeted therapies to address unmet medical needs in the treatment of CNS diseases.

What Products and Services Does NTHI Offer?

• Develop novel molecular technology for targeted drug delivery.
• Focus on treating central nervous system (CNS) diseases.
• Develop NEO100, currently in Phase 2a clinical trials for glioblastoma.
• Develop NEO212, which has completed preclinical testing.
• Aim to improve treatment outcomes for patients with CNS disorders.
• Create more effective and targeted drug delivery systems.
• Enhance drug delivery directly to the tumor site.

How Does NTHI Make Money?

• Develop proprietary molecular technologies for targeted drug delivery.
• Conduct preclinical and clinical trials to evaluate the safety and efficacy of their drug candidates.
• Seek regulatory approval from agencies like the FDA to commercialize their products.
• Potentially partner with larger pharmaceutical companies for co-development and commercialization.

What Industry Does NTHI Operate In?

Neonc Technologies Holdings, Inc. operates in the biotechnology industry, which is characterized by intense competition, high R&D costs, and lengthy regulatory approval processes. The market for CNS therapeutics is substantial, driven by an aging population and increasing prevalence of neurological disorders. The company's focus on targeted drug delivery positions it within a growing segment of the market seeking to improve the efficacy and reduce the side effects of existing treatments. Success in this space requires strong scientific expertise, robust clinical trial data, and effective commercialization strategies.

Who Are NTHI's Key Customers?

• Hospitals and cancer centers that treat patients with glioblastoma.
• Patients suffering from central nervous system diseases.
• Pharmaceutical companies seeking to license or acquire novel drug delivery technologies.
• Healthcare providers prescribing treatments for CNS disorders.

ROE 284%Key Financial Metrics

Return on equity for Neonc Technologies Holdings, Inc. stands at 284.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -25.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.08 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -38.1%, the inverse of the P/E and a quick read on earnings relative to price.

Neonc Technologies Holdings, Inc. (NTHI) Valuation Context

Valued at $87.78M, NTHI is classified as a micro-cap stock. Relative to its peer group, NTHI's quantitative score of 28/100 is below the peer average of 79/100.

Company Profile

Neonc Technologies Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Calabasas, US. The company is led by CEO Amir Farrokh Heshmatpour. NTHI has traded publicly since 2025.

F-Score 1/9Financial Health

Neonc Technologies Holdings, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

FY2026 estForward Outlook

Wall Street analysts project Neonc Technologies Holdings, Inc. revenue of about $40K for fiscal 2026, with EPS near $-0.70. The estimate reflects 4 contributing analysts.

NTHI Financials

NTHI Latest News

NTHI Analyst Consensus

NTHI MoonshotScore

What Investors Ask About Neonc Technologies Holdings, Inc. (NTHI) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources